The Galilee-based company combines excellent science and innovation to develop breakthrough immunotherapies and a pioneering intracellular drug delivery platform for cancer patients. Biond's in-house research uncovers immunoregulatory pathways and immune checkpoints, leading to the discovery of novel immune evasion mechanisms. Their transformative intracellular delivery platform for biologics allows them to target intracellular targets that were previously considered "undruggable." Biond aims to address unmet medical needs by translating high-quality science into innovative drugs that combat critical disorders and conditions.